Join our daily newsletter At The Bell to receive exclusive market insights
- Therapeutic antibody development company Patrys (PAB) identifies and selects an optimised stable cell line for production of its PAT-DX3 antibody
- The company says establishing the stable cell line for the production of PAT-DX3 has come ahead of schedule and means it company can now look at developing a commercial-scale manufacturing process
- Last year, a pre-clinical study showed PAT-DX3 was able to deliver anti-cancer drugs into mice with human breast cancer
- Patrys says it is exploring partnering opportunities for the antibody to be used in drug conjugates
- PAB shares up 8.7 per cent to 2.5 cents
Patrys (PAB) has identified and selected an optimised stable cell line for the production of its PAT-DX3 antibody ahead of schedule.
The company said establishing the stable cell line paves the way for it to start work on developing a commercial-scale manufacturing process for the PAT-DX3 deoxymab, which is needed to begin clinical development.
Studies to date suggest PAT-DX3 has the potential to be used as both a therapeutic agent and as a targeting agent to deliver anti-cancer drugs to tumours, including crossing the blood brain barrier in animal models of brain cancer and penetrating cancer cells.
In October last year, Patrys said a pre-clinical study showed PAT-DX3 was able to deliver anti-cancer drugs into mice with human breast cancer.
The company said as a result it was exploring partnering opportunities for PAT-DX3 to be used in antibody drug conjugates.
Managing Director and CEO Dr James Campbell said the company was “delighted” to have identified significantly ahead of schedule the high-yielding stable cell line for the production of PAT-DX3.
“With this key reagent now identified and in hand, we can rapidly move into developing a commercial-scale production process to support both the clinical and partnering opportunities we have for PAT-DX3,” he said.
“Most of the therapeutic antibodies in the market today are full-sized IgGs, which should provide a rich experience base for facilitating the development of a process for the large-scale production of clinical grade PAT-DX3 deoxymab.”
PAB shares were trading 8.7 per cent higher at 2.5 cents at 1:07 pm AEDT.
